RAMiller

RAMiller is a clinical-stage biotechnology company focused on developing innovative small molecule therapeutics for treatment-refractory cancers and rare neuromuscular diseases. Co-founded by University of Tennessee Health Science Center researchers Duane Miller and Ramesh Narayanan, the company leverages a proprietary platform of next-generation androgen receptor (AR) molecular glue degraders. These compounds are designed to target the non-canonical N-terminus domain of the AR, allowing for the simultaneous antagonism and degradation of both wild-type and splice-variant receptors. This approach addresses key resistance mechanisms in advanced prostate cancer, triple-negative breast cancer, and Kennedy's disease (SBMA). The company's pipeline includes lead candidates RAM-004 and RAM-005, which are advancing through clinical development to provide durable therapeutic solutions for patients with high unmet medical needs.